First Citizens BancShares Inc vs Eli Lilly And Co — how do they compare? First Citizens BancShares Inc trades at $2,066.27 (market cap $22.95B), while Eli Lilly And Co trades at $1,162.56 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 46.2× First Citizens BancShares Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and Eli Lilly And Co for 93 Days on average.
| FCNCA | LLY | |
|---|---|---|
Market Cap | $22.95B | $1.06T |
Volume | 65,288 | 2,297,239 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $1.28K |
52-Week Low | $1.64K | $799.57 |
Typical Hold Time | 29 Days | 93 Days |
Dividend Yield | 0.41% | 0.58% |
Enterprise Value | — | $1.11T |
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,071.56, down 0.79% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with a P/E of 11.11 and net income margin of 25.23%, and has beaten EPS estimates for the last three quarters. Recent corporate actions include a $2.10 dividend and expansion through branch acquisitions and new financing initiatives.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but near-term technical weakness and high institutional hold ratings suggest caution. Key risks include execution of growth initiatives and broader economic pressures on banking.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →